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Background
cGMP-dependent protein kinase (PKG) is a serine/
threonine kinase which is potently activated by cGMP
[1]. PKG is encoded by two genes, forming two different
proteins, PKGI and PKGII. The two isoforms of PKGI,
PKGIa and PKGIb, differ in the N-terminal amino acid
sequences. PKGI isozymes are homodimers with two
identical subunits possessing a catalytic and a regulatory
domain each. The regulatory domain contains two non-
identical binding sites for cyclic nucleotides (cNMPs),
i.e., a slowly exchanging and a rapidly exchanging site.
The activation constant (Ka) of PKGIa for cGMP is
about 3-fold lower than the corresponding Ka of PKGIb
suggesting distinct physiological roles of the isoforms. In
addition to cGMP, other cNMPs and also cNMP analo-
gues activate or inhibit PKG [2-4]. While many investi-
gations focussed on discrimination between the cNMP
binding sites by employing cGMP and cAMP analogues,
little is known about interaction of PKGIa with cCMP
analogues or with Rp- and Sp- diastereomers of cCMP
phosphorothioates.
As was shown by Desch et al. [5], the membrane-perme-
able cCMP analogue dibutyryl-cCMP (DB-cCMP) induces
smooth muscle relaxation and activates PKGI in aortic tis-
sue lysates. Therefore, we have studied 4-MB-cCMP, the
resulting active metabolite after cleavage of DB-cCMP by
esterases, and also corresponding substances from cAMP
and cGMP, on purified PKGIa.
Materials and methods
PKG kinase activity was measured in-vitro by a radio-
metric kinase assay in the presence of cGMP or different
cNMP analogues. pEC50 values, Ka, Hill slopes and Emax
values were calculated using GraphPad Prism software.
Emax values were related to Emax values of the activation of
PKGIa by cGMP, which was set to 1.00.
Results and discussion
Besides the known activator cGMP, many other cNMPs
and cNMP analogues are activators of PKGIa, with dis-
tinct activation constants (pEC50), specific Hill slopes
and different maximal effects (Emax) (Table 1). The most
potent and effective activator for PKGIa was cGMP.
The active metabolite of DB-cGMP, 2-MB-cGMP was
less potent and effective.
cAMP and 6-MB-cAMP showed similar potency, but
6-MB-cAMP had a higher efficacy than cAMP. 4-MB-
cCMP was a more effective activator than cCMP, but
showed a reduced potency.
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Table 1 pEC50, Ka, Hill slopes and Emax for the activation
of PKGIa by cNMPs.
cNMP pEC50 Ka (µM) Hill slope Emax
cGMP** 6.98 ± 0.04 0.11 1.71 ± 0.36 1.00 ± 0.04
2-MB-cGMP 5.84 ± 0.13 1.45 1.12 ± 0.34 0.66 ± 0.03
cAMP** 4.82 ± 0.11 15.13 1.28 ± 0.39 0.59 ± 0.05
6-MB-cAMP 4.67 ± 0.06 21.38 1.35 ± 0.19 0.81 ± 0.03
cCMP** 4.58 ± 0.14 26.30 1.84 ± 0.53 0.55 ± 0.04
4-MB-cCMP 4.05 ± 0.10 89.13 1.10 ± 0.23 0.71 ± 0.06
Sp-cAMPS 3.72 ± 0.61 190.55 1.38 ± 2.86 0.16 ± 0.01*
Rp-cAMPS n.d. n.d. n.d. n.d.
Sp-cCMPS 3.53 ± 0.97 295.12 1.11 ± 1.34 0.17 ± 0.02*
Rp-cCMPS n.d. n.d. n.d. n.d.
cIMP** 4.72 ± 0.04 19.05 1.54 ± 0.16 0.87 ± 0.02
cUMP** 4.15 ± 0.04 70.79 0.85 ± 0.21 0.72 ± 0.03
cXMP** 3.98 ± 0.04 104.71 2.06 ± 1.93 0.69 ± 0.03
*: value shows the maximum activation with 3 mM cNMP without saturation
of the concentration/response curve
**: data from Wolter et al, Biochem Biophys Res Commun. 2011, 415: 563-566.
n.d.: not determinable because of lack of saturation of the concentration/
response curve.
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The cNMP analogues activated PKGIa in the order of
potency cGMP > 2-MB-cGMP > cAMP > 6-MB-cAMP
> cCMP > 4-MB-cCMP and in the order of efficacy
cGMP > 6-MB-cAMP > 4-MB-cCMP > 2-MB-cGMP >
cAMP > cCMP.
Rp-cAMPS and Rp-cCMPS did not activate PKGIa. The
stable phosphorothioates Sp-cAMPS and Sp-cCMPS
activated PKGIa only at high concentrations in the order
of potency and efficacy cGMP > cAMP > cCMP >
Sp-cAMPS ~ Sp-cCMPS.
Furthermore, we illustrate binding of cNMPs for PKG
based on existing crystal structures and discuss current
problems with respect to molecular modelling approaches.
In conclusion, 4-MB-cCMP is a more effective PKG acti-
vator than cCMP and, therefore, a valuable tool for analys-
ing the second messenger role of cCMP [6].
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